Preveon

 

Topic mentions per year

Topic mentions per year

1997-1999
024619971999

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
  • Research initiative, treatment action : RITA
  • 1999
Data on Gilead's anti-HIV drug, adefovir dipivoxil (Preveon), were presented at the 12th International Conference on Antiviral… (More)
Is this relevant?
1999
1999
Several new anti-HIV drugs have received Food and Drug Administration (FDA) approval in the past three years, following a period… (More)
Is this relevant?
1999
1999
The FDA's Antiviral Drugs Advisory Committee voted against approval of adefovir dipivoxil (Preveon) for treating HIV. Although… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy featured information on new antiretroviral treatments… (More)
Is this relevant?
1998
1998
  • AIDS treatment news
  • 1998
Gilead Sciences has modified its expanded access program for its experimental antiviral adefovir dipivoxil (Preveon). Entry… (More)
Is this relevant?
1998
1998
Gilead Sciences is removing the CD-4 and viral load requirements for people to enter its expanded access program for adefovir… (More)
Is this relevant?
1998
1998
Gilead Sciences has seen beneficial results from two trials of adefovir dipivoxil (Preveon) in the treatment of HIV. An… (More)
Is this relevant?
1998
1998
  • Enid Vázquez
  • Positively aware : the monthly journal of the…
  • 1998
Gilead Science's adefovir (Preveon) is the first nucleotide analog to be made available through an expanded access program. The… (More)
Is this relevant?
1998
1998
  • Positively aware : the monthly journal of the…
  • 1998
Several new drugs and immune therapies are targeted for Food and Drug Administration (FDA) approval in late 1998, including a… (More)
Is this relevant?
1997
1997
  • AIDS treatment news
  • 1997
Adefovir dipivoxil (Preveon), a nucleotide analog and a prodrug of PMEA, has been approved for a limited expanded access program… (More)
Is this relevant?